Stay updated on Imprime PGG+Pembrolizumab in Melanoma & TNBC Clinical Trial
Sign up to get notified when there's something new on the Imprime PGG+Pembrolizumab in Melanoma & TNBC Clinical Trial page.

Latest updates to the Imprime PGG+Pembrolizumab in Melanoma & TNBC Clinical Trial page
- Check6 days agoNo Change Detected
- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedAdded a government funding lapse notice and a v3.2.0 version tag, replacing the prior v3.1.0.SummaryDifference2%

- Check28 days agoChange DetectedVersion update: from v3.0.2 to v3.1.0. The change is limited to the revision label; no core content or critical data appears to be altered.SummaryDifference0.0%

- Check42 days agoChange DetectedThe page version updated from v3.0.1 to v3.0.2. The Back to Top element was removed, with no changes to core content.SummaryDifference0.1%

- Check49 days agoChange DetectedThe page has updated the publication date of a significant clinical trial article from May 8, 2025, to July 1, 2025, and has revised the version number from v3.0.0 to v3.0.1.SummaryDifference0.3%

- Check57 days agoChange DetectedThe web page has been updated to include a new facility name and location, along with a significant publication related to a clinical trial involving pembrolizumab for metastatic triple negative breast cancer. Additionally, the revision number has been updated to v3.0.0.SummaryDifference5%

- Check71 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.0%

Stay in the know with updates to Imprime PGG+Pembrolizumab in Melanoma & TNBC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Imprime PGG+Pembrolizumab in Melanoma & TNBC Clinical Trial page.